Indapta Therapeutics Inc.
Houston, TX · CIK 0001910175 · Biotech · Private
Off-the-shelf allogeneic FcRγ-deficient natural killer cell therapy for cancer and autoimmune diseases
indapta.com →- Grants
- $600K
- 2 awards
- Sector median: 1
- Raised
- $84M
- 2 Form D · Oct 2025
- 12 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 38
- 3 granted · 35 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023202420252026
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Translational development of specialized NK cells for cancer immunotherapy | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Immuno Oncology Product for Multiple Myeloma: g-NK Cellular Therapy to Optimize Monoclonal Antibody Efficacy in Treating Multiple | $300,000 | |
| Private capital raised | Form D · SEC | $33,603,097 | |
| Private capital raised | Form D · SEC | $50,800,176 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2120 | Sonoma Biotherapeutics | — | $265M |
| 2121 | ARVINAS, INC. | — | $129M |
| 2122 | ARBOR EQUITY GROUP FUND I, LP | — | $500K |
| 2123 | Indapta Therapeutics Inc. | — | $84M |
| 2124 | PERIOMICS CARE LLC | — | — |
| 2125 | Apricity Therapeutics | — | — |
| 2126 | Lygos, Inc. | — | $41M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Guy DiPierroExecutive Officer
- Mark FrohlichDirector · Executive Officer
- Lori HuDirector
- Ronald MartellDirector
- Fabio PucciDirector
- Laura StoppelDirector
Patents
- Engineered Natural Killer (nk) Cells And Compositions And Methods Thereofgranted
- Methods For Expansion Of Natural Killer (nk) Cell Subset And Related Compositions And Methodsapplication
- Combination Of Engineered Natural Killer (nk) Cells And Antibody Therapy And Related Methodsapplication
- Methods For Expansion Of Natural Killer (nk) Cell Subset And Related Compositions And Methodsgranted
- Engineered Natural Killer (nk) Cells And Related Methodsapplication
- Methods Of Treatment And Dosing Of Natural Killer Cell Compositionsapplication
- Engineered Natural Killer (nk) Cells And Compositions And Methods Thereofgranted
- Natural Killer (nk) Cell Compositions And Methods For Generating Sameapplication
- Subsets Of Human Natural Killer Cells With Enhanced Antibody-directed Immune Responsesapplication
- Treatment Of Autoimmune Diseases Or Conditions With Natural Killer Cellsapplication
- Treatment Of Autoimmune Diseases Or Conditions With Natural Killer Cellsapplication
- Method Of Treating Cancer With Natural Killer Cellsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.